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Abstract
Background: Postpoliomyelitis Syndrome (PPS) is a complex of late onset neuromuscular symptoms with new
or increased muscle weakness and muscle fatigability as key symptoms. Main clinical complaints are severe
fatigue, deterioration in functional abilities and health related quality of life. Rehabilitation management is the
mainstay of treatment. Two different therapeutic interventions may be prescribed (1) exercise therapy or (2)
cognitive behavioural therapy (CBT). However, the evidence on the effectiveness of both interventions is
limited. The primary aim of the FACTS-2-PPS trial is to study the efficacy of exercise therapy and CBT for
reducing fatigue and improving activities and quality of life in patients with PPS. Additionally, the working
mechanisms, patients’ and therapists’ expectations of and experiences with both interventions and cost-
effectiveness will be evaluated.
Methods/Design: A multi-centre, single-blinded, randomized controlled trial will be conducted. A sample of
81 severely fatigued patients with PPS will be recruited from 3 different university hospitals and their
affiliate rehabilitation centres. Patients will be randomized to one of three groups i.e. (1) exercise therapy +
usual care, (2) CBT + usual care, (3) usual care. At baseline, immediately post-intervention and at 3- and 6-
months follow-up, fatigue, activities, quality of life and secondary outcomes will be assessed. Costs will be
based on a cost questionnaire, and statistical analyses on GEE (generalized estimated equations). Analysis
will also consider mechanisms of change during therapy. A responsive evaluation will be conducted to
monitor the implementation process and to investigate the perspectives of patients and therapists on both
interventions.
Discussion: A major strength of the FACTS-2-PPS study is the use of a mixed methods design in which a
responsive and economic evaluation runs parallel to the trial. The results of this study will generate new evidence
for the rehabilitation treatment of persons with PPS.
Trial registration: Dutch Trial Register NTR1371.
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Background
Poliomyelitis anterior acuta is an acute viral disease that
attacks the anterior horn cells of the spinal cord and the
motor neurons of the lower brain stem resulting in flac-
cid paresis or paralysis. Usually there is partial and
sometimes complete recovery from the self-terminating
disease. However, many people with a history of polio-
myelitis report late onset neuromuscular symptoms and
a decline in functional abilities. These late symptoms
are referred to as Postpoliomyelitis Syndrome (PPS) and
include new or increased muscle weakness, abnormal
muscle fatigability, generalized fatigue, muscle atrophy,
muscle and joint pain, muscle cramps and cold intoler-
ance [1].
The prevalence of PPS has been reported from 15% to
80% of all patients with previous paralytic polio depend-
ing on the criteria applied and population studied [2].
Nearly 60% of a sample of Dutch survivors of the 1956
polio outbreak experience late onset polio sequelae [3].
In Western countries, where the large epidemics date
back to the 1940s and 1950s, many polio survivors are
now experiencing progressive complaints related to PPS.
The World Health Organization (WHO) estimates that
10 to 20 million polio survivors are alive worldwide, and
some estimates suggest that 4 to 8 million of them may
develop PPS [4]. Although, the efforts of the Global
Polio Eradication Initiative of the WHO initiated in
1988, led to an enormous reduction in the number of
acute polio cases globally ever since, polio is still a rele-
vant problem. In Western Africa and in South Asia
polio is still endemic and spread of the virus from these
countries causes new outbreaks in countries that were
certified as polio free. Therefore, new cases of PPS can
be anticipated in the coming decades.
Fatigue is one of the most frequent complaints of PPS
[5-7] and it is typically described as tiredness or lack of
energy that increases with physical activity and
decreases with rest [8]. In a study on disability and
health problems in 76 Dutch patients with PPS, 78% of
the subjects selected fatigue as their major problem [9].
Subjects with PPS experience higher levels of fatigue
than healthy controls [10,11]. Fatigue has a negative
impact on activities of daily living and there is evidence
that post-polio related fatigue is an important factor for
the reduced health related quality of life (HRQoL) in
polio survivors [12].
In current practice, rehabilitation management is the
mainstay of treatment for PPS. Rehabilitation aims to
improve patients’ capacities to perform activities of daily
living and adapt performance (i.e. actual behaviour) to
the available capacities. We expect that a reduction of
the imbalance between patients’ capacities and perfor-
mance will lead to a reduction in fatigue and
improvement in activities and HRQoL. There are two
possible approaches to achieve this goal; exercise ther-
apy and cognitive behavioural therapy (CBT). However,
evidence to support the effectiveness of either approach
is still limited.
The insufficient evidence to support exercise consists
of contradictory and incomplete information in the lit-
erature. On the one hand, PPS patients are advised to
avoid muscular overuse and intensive training as this
could worsen symptoms such as muscle weakness and
fatigue and provoke a further loss of muscular strength
[1]. On the other hand, physically active PPS patients
were found to have less symptoms of fatigue than
sedentary patients [13]. It is unclear whether symptoms
of fatigue are cause or result of physical inactivity. A
systematic review on exercise therapy for neuromuscular
diseases included ten studies on muscle strengthening
exercises and aerobic exercises in PPS of which five
demonstrated significant positive effects on muscular
strength and aerobic capacity without generating any
adverse effects. However, all these studies had to be
qualified as having insufficient or limited methodological
quality [14]. This led to the conclusion that there is
insufficient evidence for the effectiveness of exercise for
patients with PPS and that future, preferably multi-cen-
tre, studies are needed. A recent study on the short-
term effectiveness of home- and hospital- based aerobic
exercise showed improvement on fatigue and quality of
life [15]. However results were not compared with a
control group and long-term effectiveness was not eval-
uated in this study.
There is broad evidence for the effectiveness of CBT
in reducing fatigue in chronic fatigue syndrome, fatigued
post cancer survivors and multiple sclerosis [16-19].
However, there are no studies of CBT for fatigue in PPS.
The evidence for a cognitive behavioural approach in
PPS is currently limited to results from an uncontrolled
pilot study in which cognitive behavioural strategies are
incorporated in a comprehensive multidisciplinary reha-
bilitation program [20]. Although significant reductions
in fatigue symptoms were found, it is unclear whether
these effects can be ascribed to the cognitive behavioural
components of the intervention.
We anticipate that exercise therapy and CBT are both
effective in reducing fatigue and improving activities and
HRQoL in patients with PPS compared to the usual
care. The FACTS-2-PPS study aims to give insight in
the efficacy of both interventions for patients with PPS.
As secondary outcomes, the working mechanisms,
patients’ and therapists’ expectations of and experiences
with both interventions and cost-effectiveness will be
evaluated. These aims have led to the following research
questions:
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(1) Does exercise therapy for patients with PPS
reduce fatigue and improve activities and HRQoL as
compared to usual care?
(2) Does CBT for patients with PPS reduce fatigue
and improve activities and HRQoL as compared to
usual care?
(3) What are the generic and disease-specific deter-
minants for treatment success of exercise therapy
and CBT?
(4) What are patients’ expectations of and experi-
ences with exercise therapy and CBT?
(5) What is the cost-effectiveness of exercise therapy
and CBT compared to usual care?
Methods/Design
Study design
A multi-centre, single-blinded randomized controlled
trial (RCT) with 6 months follow-up will be conducted
to evaluate the efficacy of exercise therapy and CBT
compared to usual care in patients with PPS (Figure 1).
To gain insight into patients’ expectations and experi-
ences, a responsive evaluation will be conducted. To
determine the cost-effectiveness, an economic evaluation
will be conducted alongside this RCT. The study proto-
col was approved by the Medical Ethics Committee of
the Academic Medical Centre (AMC) and all participat-
ing centres granted approval to participate.
Study population
All patients will be recruited from outpatient clinics of
the AMC Amsterdam; the University Medical Centre
Utrecht (UMCU); the University Medical Centre Nijme-
gen (UMCN) or the affiliate rehabilitation centres. Case
histories are checked to screen for potentially eligible
patients. Patients willing to give signed consent are evalu-
ated by a physician to check in and exclusion criteria
(Table 1). The sample size was calculated for this three-
arm trial based on the comparison treatment (exercise
therapy or CBT) versus usual care, with equal allocation
across treatment arms and 4 repeated measurements (at
entry (pre-treatment), at 4 months (post-treatment), at 3
Figure 1 Study design.
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months follow-up (short-term follow-up) and at 6
months follow-up (long-term follow-up), respectively),
with an estimated correlation coefficient of the repeated
measurements of rho = 0.79 (based on unpublished data
from a reproducibility study in 37 PPS patients), a clinical
relevant improvement of 8 points on the CIS-fatigue scale
(for both treatments) [17] and an estimated standard
deviation in each treatment group of 9.3. The total sam-
ple size needed to detect this difference on a 5% level of
significance (two tailed) with a power of 90% was 24 sub-
jects in each group [21]. We expect a drop-out rate of
maximal 10%, based on a previous trial in this patient
group [22]. Therefore 81 patients will be recruited.
Randomization and blinding
Patients will be assigned to the rehabilitation centre that
is nearest to their home village. Randomization will be
stratified per centre. Patients fulfilling both inclusion
and exclusion criteria will be randomized to one of
three groups: (1) exercise therapy + usual care, (2) CBT
+ usual care, or (3) usual care. The randomization
scheme is computer-generated and will be done by
creating random blocks of sequences with variable block
sizes of 3 and 6. The investigator who will perform the
randomization will inform the patient and, in case of
allocation to exercise therapy or CBT also the therapist
of the group allocation.
The investigators that are responsible for the inclusion
will be blinded. Outcomes will be assessed by blinded
and independent outcome assessors. At the beginning of
the assessment patients will be instructed not to reveal
their group allocation to the investigators. To evaluate
the success of blinding, the investigator will be asked at
each measurement, to guess the treatment assignment
of the patient, with options ‘CBT’, ‘exercise therapy’,
‘usual care only’ and ‘unknown’. Analyses will be per-
formed blinded for treatment allocation.
Interventions
Usual care
The patients in the control and intervention groups will
all receive usual care. Usual care for PPS patients may
include usage of assistive devices, orthoses, physical
therapy, and medication. Patients will not be restricted
in their activities. Co-interventions will be monitored
throughout the study.
Exercise therapy
Exercise therapy is designed specifically to enhance phy-
sical capacity. The intervention has a duration of 16
weeks and consists of (1) a home-based aerobic training
program three times weekly and a (2) supervised group
training consisting of muscle strengthening and func-
tional exercises once a week. The therapy will be super-
vised by specifically trained physiotherapists. An
unblinded member of the project group will supervise
the therapists and perform integrity checks on each
treatment location.
(1) The home-based training program consists of indi-
vidually tailored aerobic exercise on a cycle ergometer.
Patients will be supplied with a cycle ergometer, a log
book with training instructions and a training scheme at
home. Heart rate will be continuously measured with a
heart rate monitor. Furthermore, in the log book
patients will document the number and duration of
treatment sessions, the training load, perceived exertion
on the Borg Rated Perceived Exertion Scale [23] and
possible complaints after the training session. Training
intensity will be gradually increased from 60% of the
Heart Rate Reserve (HRR) to 70% HRR, in accordance
with the American College of Sports Medicine guide-
lines for aerobic training in healthy adults [24] and per-
sons with chronic diseases and disabilities [25]. The
duration of the training sessions will gradually be
increased from 20 to 30 minutes per session and ses-
sions are divided into prescribed exercise bouts which
are interspersed with short rest periods of unloaded
cycling. The duration of exercise bouts will be gradually
increased from 2 minutes at the start of the program to
13 minutes at the end of the program.
Warming-up and cooling-down consists of 5 minutes
unloaded cycling. Feasibility of the training schemes is
weekly checked by one of the therapists by reading out
the heart rate monitors and checking the log books.
When necessary, adjustments to the training schemes
will be made.
(2) The supervised group training consists of individu-
ally tailored muscle strengthening exercises and
Table 1 In- and exclusion criteria
Inclusion criteria
(1) diagnosis of PPS according to the criteria of March of Dimes [1]
(2) severe perceived fatigue (CIS-fatigue > = 35) [47]
(3) age between 18 and 75 years
(4) life-expectancy longer than one year
(5) walking-ability at least indoors with or without a walking aid
(6) ability to cycle on a cycle ergometer against a load of at least 25
Watt
Exclusion criteria
(1) use of psychotropic drugs or other psychiatric treatment
(2) clinical depression (BDI-PC > 6) [48]
(3) disabling co-morbidity interfering with the intervention programs or
influencing outcome
parameters (including cardiopulmonary disease, epileptic seizures,
poorly regulated diabetes mellitus)
(4) respiratory insufficiency (FVC < 50%pred or CO2 retention) or
assisted ventilation
(5) cognitive impairment
(6) insufficient mastery of the Dutch language
(7) pregnancy
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functional exercises in 1-hour group sessions. Sessions
will be divided into a 5-minute warm-up period of aero-
bic exercises, 30 minutes of muscle strengthening, 20
minutes functional exercises and a 5-minute cool-down
period. Muscle strengthening exercise selection and
dosage will be determined by the therapist at a separate
visit to the treatment location before the start of the
program. Muscle groups and accompanying exercises
will be selected based on patients MRC-scores [26] and
reported problems in daily activities. Exercises are
selected based on the best expected effects on physical
functioning.
Muscle groups with MRC scores less then 3 are not
selected and quadriceps muscles are always selected
when this muscle group has a MRC score of at least 3.
Training load will be based on the 1-RM test [27]. In
the first 4 weeks, training load will be 50% of 1-RM,
each exercise consists of 3 sets with 2 minutes rest
between a set and number of repetitions will be
increased from 8 to 20 during 4 weeks. When the
desired number of repetitions with the current load is
reached, training load is increased in week 5 and 9 to
60 and 70% respectively, and the number of repetitions
is increased in the same manner as prescribed for the
first 4 weeks [28].
Cognitive behavioural therapy
CBT will be directed at frequently reported perpetuating
factors of fatigue in slowly progressive neuromuscular
disorders [29]. They may involve dysfunctional cogni-
tions with respect to the disease itself, to pain and to
fatigue [30], dysfunctional attention to pain or fatigue
symptoms, deregulation of sleep [30,31], deregulation of
physical, social and/or mental activities [30,31], and low
social support and negative social interactions [32]. For
each factor a standardized module is available as part of
the intervention. Because of the variability of relevant
perpetuating factors in PPS patients, therapy will be cus-
tomized to each individual. To determine which mod-
ules will be necessary, each perpetuating factor will be
measured with specific questionnaires (Table 2). The
number of sessions will be determined by the number
of modules used and will vary between 12 and 16 ses-
sions, each with a duration of 1 hour during a 4 months
period. Experienced cognitive behavioural therapists will
treat the patients. The therapists will be trained in the
protocol and the use of instruments to determine which
module should be included in the therapy. Role-playing
is an important part of this training. In the first CBT
session individualized concrete behavioural goals of the
therapy are formulated by the patient with help of the
therapist. These goals are formulated in terms of con-
crete behaviours the patient wants to perform if he is
not extremely fatigued anymore. Appendix 1 gives an
overview of cognitive and behavioural techniques that
can be used during CBT for each perpetuating factor of
fatigue.
Compliance and attrition
Compliance will be assessed by recording the number of
treatment sessions (CBT or group exercise sessions)
attended and, for the patients randomized to exercise
therapy, also the total time spent to aerobic exercise on
the bicycle ergometer at home will be recorded in a log
book.
Outcomes
Efficacy and working mechanisms
Outcome measures are presented in Table 3. Our pri-
mary outcome measure is fatigue. Additionally, daily
activity performance and HRQoL will be evaluated. Sec-
ondary outcomes are categorised in accordance with the
International Classification of Functioning (ICF) [33] on
Table 2 Instrumentation for module selection CBT
Perpetuating factor for
fatigue
Instrumentation
1. Dysfunctional cognitions
with respect to the disease
Impact of Event Scale [49]
Pictorial Representation of Self and
Illness Measure (PRISM) [50]
Illness Cognitions Questionnaire (ICQ)
[51]
2. Dysfunctional cognitions
with respect to pain
Medical Outcome Study 36-Item Short-
Form Health Survey (SF-36; domain:
pain) [52]
Daily Observed Pain (DOP) [53]
Pain Catastrophizing Scale (PCS) [54]
3. Dysfunctional cognitions
with respect to fatigue
Self-Efficacy Scale [18]
Jacobsen Fatigue Catastrophizing Scale
(J-FCS) [55]
4. Dysfunctional attention to
fatigue and pain
Illness Management Questionnaire
(IMQ) [56]
5. Deregulation of sleep Sickness Impact Profile (SIP; domain:
sleep and rest) [57]
Symptom Checklist-90 (SCL-90; domain:
sleep) [58]
6. Deregulation of physical
activities
Chronic Fatigue Syndrome-activity
questionnaire (CFS-AQ; domain:
physical activity) [59]
7. Deregulation of social
activities
Medical Outcome Study 36-Item Short-
Form Health Survey (SF-36; domain:
social functioning) [52]
Chronic Fatigue Syndrome-activity
questionnaire (CFS-AQ; domain social
activity) [59]
Sickness Impact Profile (SIP; domain:
social interaction) [57]
8. Deregulation of mental
activities
Checklist Individual Strength (CIS;
domain: concentration) [47]
Sickness Impact Profile (SIP; domain:
alertness/intellectual functioning) [57]
Chronic Fatigue Syndrome-activity
questionnaire (CFS-AQ; domain: mental)
[59]
9. Low social support and
negative social interactions
Social Support Inventory-Interactions
(SSL-I_08) [60]
Social Support Inventory-Discrepancies
(SSL-D_08) [60]
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the level of body functions, activities and participation
and personal factors. As potential effect modifiers the
following parameters will be studied; demographic vari-
ables, main complaints of PPS, disease severity, co-mor-
bidity, serum creatine kinase activity and the ICF
environmental factors; social support, HRQoL of the
partner, coping of the partner and caregiver burden.
Two secondary outcome measures on the level of body
functions; cardio-respiratory fitness and neuromuscular
capacity will be described in greater detail.
Cardio-respiratory fitness
Subjects will perform a submaximal exercise test on a
cycle ergometer (Lode Corival, Groningen, The Nether-
lands). The test starts with unloaded pedalling for three
minutes, followed by a 10 Watt increment every single
minute and will be terminated if one of the following
occurs: (1) achieving 80% HRR or, (2) pedalling fre-
quency dropping below 60 rpm, or (3) not being able to
continue the test for any reason. The same workload
protocol will be applied at the follow-up measurements.
Throughout the test, gas exchange variables (COSMED
K4b2, Rome, Italy) and heart rate will be measured con-
tinuously. Cardio-respiratory fitness will be determined
based on changes in heart rate and gas exchange
variables.
Neuromuscular capacity
Maximal voluntary contraction (MVC) of the quadriceps
muscle will be measured isokinetically between 90° and
30° knee flexion using a fixed dynamometer (Biodex
System 3, New York, USA). To determine MVC, sub-
jects will perform three maximal-effort knee extensions
at an angular velocity of 60°/sec. The highest value of
peak torque (Nm) will be used for the analyses.
In addition, under isometric conditions, voluntary acti-
vation (VA) will be measured with a modified superim-
posed stimulation technique [34]. The quadriceps
muscle will be electrically stimulated transcutaneously
with surface electrodes placed over the proximal and
distal part of the anterior thigh and using a computer-
controlled constant current stimulator (Digitimer DSH7,
Welwyn garden City, UK). A triplet (pulse train of three
200 μs pulses applied at 300 Hz with a supramaximal
stimulation current) will be superimposed on a 3-4s
maximal isometric knee extension at 60° knee flexion.
An identical stimulation will be delivered to the relaxed
quadriceps muscle to evoke a resting (control) triplet.
Voluntary activation will be calculated by the following
formula:
VA superimposed triplet control triplet(%) ( ( / )) %  1 100
Fatigability of the quadriceps muscle will be deter-
mined by fatiguing the muscle by a series of electrically
stimulated contractions. The current will be reduced
such that a single tetanus at 150 Hz evokes approxi-
mately 30-50% of maximal isometric strength. A series
of trains of 50 Hz stimulation (duration 1000 ms, with
1000 ms between trains) will be applied for a period of
300 seconds (150 contractions in total). Recovery of fati-
gue will be monitored by applying the same 50 Hz train
(1000 ms duration) at different times (15 sec up to 3
min) after the end of the protocol. Changes in force,
maximal rate of force rise and half relaxation time will
be determined. These parameters will be expressed as a
percentage of the values obtained in the first contraction
of the protocol to correct for differences in muscle
strength.
Adverse events
All adverse events reported spontaneously by the parti-
cipants or observed by the therapists will be recorded.
All adverse events will be followed until they have aba-
ted, or until a stable situation has been reached.
Responsive evaluation
To gain insight into patients’ and therapists’ expecta-
tions of and experiences with both interventions, a
responsive evaluation will be conducted [35,36]. Thera-
pists and a subgroup of patients will be interviewed
about their experiences with the intervention. The selec-
tion of respondents will be based on the criterion of
‘’maximum variation” [37]. The interviews are semi-
structured, with open questions guided by a topic list.
In order to check the topic list three pilot interviews
will be conducted with patients and one with a partner.
Then patients engaged in both interventions will be
interviewed. Additionally focus groups will be organized
to validate, deepen and broaden the issues in the inter-
views, starting with two homogeneous focus groups
(converging interests) with patients and partners, and
two homogenous focus groups with therapists (one per
intervention). Then all parties will be brought together
in a heterogeneous (diverging interests) dialogue group
to exchange views. In the cyclic process data from ear-
lier phases will be used as input for the next phase; this
hermeneutic dialectic interaction prevents one-sidedness
and fosters the validation of data [38]. During all phases
the interviews and focus groups will be tape-recorded,
transcribed and analyzed. The analysis will focus on the
recurring issues and concerns of all parties, and the
comparison of perspectives. Member checks will be held
to check the credibility of the analysis [37]. In order to
consult and gain advice from patient representatives
with PPS the research team will collaborate with the
Vereniging Spierziekten Nederland (Dutch patient sup-
port group), in all phases of the research process [39].
Economic evaluation
Cost-effectiveness and cost-utility will be evaluated from
a societal perspective. The costs will include direct
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health care costs of visits to general practitioners, medi-
cal specialists, therapists, medications and assistive
devices, direct non-health care costs i.e. non-reimbursa-
ble costs for complementary medicine and over-the-
counter medication, and indirect, non-health care costs
of changes in paid and unpaid work. All these data will
be collected via cost diaries.
Resource use will be valued following the procedures
outlined by the Dutch Manual of Costing [40]. Where
standard cost prices are not available, tariffs or
professional fees will be used to estimate costs. The costs
of medications will be estimated using the prices reported
by the Royal Dutch Society for Pharmacy. Productivity
loss costs from paid work will be estimated using both the
human capital approach and friction cost method. The
productivity loss costs from unpaid work will be deter-
mined using a shadow price. Cost prices of the interven-
tions will be determined by a bottom-up calculation.
The effect measures used in the economic evaluation
will be our primary outcome measure fatigue and
Table 3 Outcome measures and instrumentation
Instrumentation T1 T2 T3 T4
Primary outcome measures
Fatigue Checklist Individual Strength (CIS; domain: fatigue) [47] X X X X
Daily activity performance Sickness Impact Profile 68
(SIP-68; domains: mobility range, mobility control, social behaviour) [61]
X X X X
HRQoL Medical Outcome Study 36-Item Short-Form Health Survey (SF-36) [52] X X X X
Secondary outcome measures
ICF: Body functions
Pain Visual Analogue Scale (VAS) X X X X
Emotional states Profile of Mood States (POMS) [62,63] X X X X
Sleep disturbances Nottingham Health Profile (NHP; domain: sleep) [64] X X X X
Cardio-respiratory fitness Submaximal exercise test with cycle ergometer X X X X
Neuromuscular capacity Fixed dynamometry and electrical stimulation X X X X
ICF: Activities/Participation
Physical activity level in daily life Activity Monitor (StepWatch, Cyma, Seattle, WA) on 7 consecutive days X X X X
Perceived participation Impact on Participation and Autonomy Questionnaire (IPA) [65] X X X X
Functional Capacity Timed-Up-and-Go test (TUG) [66] and
2-minute walk test (2-MWT) [67]
X X X X
ICF: Personal Factors
Illness cognitions Illness Cognitions Questionnaire (ICQ) [51] X X X X
Coping Coping Inventory for Stressful Situations (CISS-21) [68] X X X X
General Self Efficacy General Self Efficacy Scale (ALCOS-16) [69] X X X X
Effect Modifiers
General effect modifiers
Demographic variables (age, gender, education,
ethnicity, social-economical status)
X
PPS main complaints Polio Problem List (PPL) [9] X X X X
PPS disease severity Medical Research Council scale (MRC) [26] X
Co-morbidity Cumulative Illness Rating Scale (CIRS) [70] X X X X
Serum creatine kinase activity Venipuncture X * X X X
ICF: Environmental factors
Social support Social Support Inventory (SSL-D) [60] X X X X
HRQoL (partner) Medical Outcome Study 36-Item Short-Form Health Survey (SF-36) [52] X X X X
Coping (partner) Coping Inventory for Stressful Situations (CISS-21) [68] X X X X
Caregiver Strain (partner) Caregiver Strain Index (CSI) [71] X X X X
Economic evaluation
HRQoL EuroQol-5D [41] X X X X
Resource use Cost diaries X X X X
* In the exercise group two extra blood samples will be obtained at 5 and 10 weeks.
T1; pre-treatment, T2; post-treatment, T3; short-term follow-up, T4; long-term follow-up.
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HRQoL measured with the EuroQol-5D [41] at the four
different time measurements. Utilities will be derived
using the Dutch tariffs and used to determine quality-
adjusted life years (QALYs) [42,43].
Statistical Analyses
GEE (generalized estimated equations) analyses will be
used to investigate differences in the effects (primary
and secondary outcomes) between both intervention
groups and the usual care group and to investigate asso-
ciations between potential effect modifiers and effect of
interventions. Data will be analyzed according to the
intention-to-treat principle. Missing data will be
imputed by carrying the last observation forward.
The economic evaluation will also be performed
according to the intention-to-treat principle. First, mean
differences in QALYs will be tested using parametric
tests, and uncertainty expressed by 95% confidence
intervals. Second, we will conduct between-group com-
parisons of the mean costs for each of the resource use
categories and total costs. Confidence intervals around
the mean cost differences will be obtained by a bias-cor-
rected and accelerated (Bca) bootstrapping based on
5000 replications [44]. Third, the incremental cost-effec-
tiveness ratio (ICER) will be determined by dividing the
mean difference in total costs by the mean difference in
effects. Insight into the uncertainty around the mean
ICER will be obtained by bootstrapping based on 5000
replications, the generation of cost-effectiveness planes
[45] and cost-effectiveness acceptability curves [46]. Sen-
sitivity analyses involving the most important cost dri-
vers will be performed in order to assess the robustness
of the results.
Discussion
In the FACTS-2-PPS study, the efficacy of exercise ther-
apy and CBT in reducing fatigue and improving activ-
ities and HRQoL in patients with PPS will be evaluated
in comparison with usual care. This study captures
some important strengths.
Firstly, the majority of studies on exercise in PPS eval-
uated the effects of strength or aerobic training in PPS
separately. However, to execute normal every day activ-
ities, more integrated functional tasks are necessary
requiring a combination of strength, endurance, flexibil-
ity, balance and coordination. This study evaluates a
multi-component exercise training in which aerobic,
strength and functional exercises are combined.
Secondly, although it is widely recommended that
behavioural adaptation is an important component in the
management of fatigue in PPS, there are no studies con-
firming the effectiveness of this approach. This is the first
study that will evaluate the efficacy of CBT in reducing
fatigue in PPS. The treatment protocol was developed by
investigators with broad experience with CBT for chronic
fatigue syndrome and fatigued cancer survivors, and cus-
tomized to the specific aspects of fatigue in PPS.
Thirdly, the long-term follow-up, the broad arsenal of
outcome measures on different domains of the ICF and
the inclusion of a responsive evaluation and an eco-
nomic evaluation gives this study a unique mixed meth-
ods design. Investigating patient perspectives and
possible discrepancies between perspectives of patients
and professionals will help to elaborate strong and weak
points of both interventions, which in turn might
explain specific results obtained in the study. Addition-
ally, this mixed methods design will facilitate the deci-
sion making with respect to implementation of the
results when the interventions turn out to be effective.
However, the study has also some limitations. The
sample size was based on the detection of an approxi-
mately equal effect size of exercise training and CBT in
comparison to usual care. Detecting differences in effec-
tiveness between both interventions would require
much larger sample sizes. Furthermore, the design of
this study, will not give insight into the indicators that
are helpful in decision making about tailoring
interventions.
In conclusion, the results of this study will provide
greater insight on evidence-based treatment options for
PPS. Successful outcome from the study has the poten-
tial to result in reduced fatigue and improved activities
and quality of life for patients with PPS. Results might
lead to alterations of existing international guidelines.
Appendix 1: Overview of CBT intervention
Perpetuating factors: dysfunctional cognitions with
respect to the disease, pain and fatigue
A patient can have dysfunctional cognitions, for example
unrealistic expectations on prognosis or difficulties with
the acceptation of the consequences of PPS. More fre-
quent are dysfunctional cognitions with respect to fati-
gue and/or pain. By non helping cognitions as ‘I can’t
control the fatigue’ and ‘the fatigue is terrible’, the
patient catastrophizes about fatigue thereby enlarging
the experience of fatigue. By means of cognitive restruc-
turing (Socratic dialogue and prompting new self-talk)
the patient learns to change these non helpful thoughts
into more helpful one in daily life.
Perpetuating factor: dysfunctional attention to fatigue
and pain
Many patients are alert to symptoms of fatigue (or pain).
Persons in their social environment ask the patient
about the fatigue (or pain). Information and explanation
will be given that the effect of attending to fatigue (or
pain) sensations is increasing and intensifying these
symptoms. By daily exercises the patient can learn how
to shift attention away from fatigue (or pain). Also les-
sening the attention from others for these symptoms
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will be realized. The partner of the patient may be
involved in this module.
Perpetuating factor: deregulation of sleep
An irregular sleep-wake rhythm can perpetuate fatigue.
To restore the biologic rhythm, patients will be encour-
aged to adhere to fixed bedtimes and wake-up times
and will be discouraged from sleeping during the day or
adapt fixed rest period(s).
Perpetuating factors: deregulation of physical, social and
mental activities
Polio survivors are known to have strong perseverance.
From childhood on they were learned to deny their
symptoms in order to achieve a normal life. Many of
them have difficulties adapting their physical, social and
mental activities to their decreasing abilities. First, these
patients will be thought to pace or reduce the amount
of activities. Next, graded increase of certain physical,
social or mental activities will help the patient to reach
step by step their set goals.
Perpetuating factors: low social support and negative
social interactions
Unrealistic expectations or non helpful cognitions about
the social environment (for example ‘why do I not get help
from others?’) can perpetuate fatigue. After explanation,
the therapist will help to change non helpful cognitions
and install more realistic expectations toward others in the
patient’s social environment. The partner or relevant
others may be involved in this part of the therapy.
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